Fibroblast Growth Factor Receptor 3 (FGFR3) is an attractive therapeutic target in bladder cancer given the 10–30% prevalence of FGFR3 aberrations (activating mutations or aberrant gene fusions) in these tumours, and their preclinical sensitivity to FGFR-targeted therapy [3]. Here, FGFR3 is linked to urinary bladder cancer.